AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
UMB News
Support UMB s Increasing Efforts to Deal with the COVID-19 Pandemic
During this important period, please consider supporting UMB s critical vaccine research and development, advancing its work in human virology, and donating to critical emergency funds especially designed for specific students in need.
We truly appreciate your gifts in this time of great need. February 9, 2021
Matthew B. Frieman, PhD
The vaccine was found to generate a robust immune response in animals exposed to the vaccine with strong data indicating safety and efficacy, according to the study published recently in the journal
The vaccine is a stable protein that is manufactured from the genetic sequence of the SARS-CoV-2 coronavirus spike protein. As with traditional vaccines like the flu shot, the Novavax vaccine uses adjuvants to boost the immune response in those who receive it.
Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released
An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase 3 clinical data conducted Jan. 21. The vaccine, called Ad.26.COV2.S or JNJ-78436725, requires only a single injection and can be stored in a refrigerator for months.
The interim analysis assessed 468 cases of symptomatic COVID-19 among 44,325 adult volunteers in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, and the United States. The investigational vaccine was reportedly 66% effective at preventing the study’s combined endpoints of moderate and severe COVID-19 at 28 days post-vaccination among all volunteers, including those infected with an emerging viral variant. Moderate COVID-19 was defined as laboratory-confirmed SARS-CoV-2 plus either one of the following: evidence
Analysis Demonstrates Effectiveness of LY-CoV555 Antibody in Preventing Symptomatic COVID-19
Analysis Demonstrates Effectiveness of LY-CoV555 Antibody in Preventing Symptomatic COVID-19
DURHAM, N.C., Jan. 25, 2021 Researchers from the COVID-19 Prevention Network (CoVPN) announced that the monoclonal antibody (mAb), LY-CoV555 (bamlanivimab), evaluated in a Phase III trial significantly reduces the risk of contracting symptomatic COVID-19 as well as reduces the clinical course of COVID-19 in study participants who did become symptomatic. The study, CoVPN 3501, was conducted in collaboration with Eli Lilly and Company in skilled nursing facilities (SNFs) across the United States. Residents and staff at SNFs participated in the trial.
A total of 1,097 participants (340 residents, 757 staff) were randomized to receive either a single 4,200 mg dose of LY-CoV555 or placebo (saline). Half of the study participants received LY-CoV555 and h
Share this article
Share this article
TORONTO, Jan. 21, 2021 /CNW/ - Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The Phase 3 BLAZE-2 COVID-19 prevention trial – conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH), and the COVID-19 Prevention Network (CoVPN) – enrolled residents and staff at skilled nursing and assisted living facilities, commonly referred to as nursing homes, across the U.S.
The 965 participants who tested negative for the SARS-CoV-2 virus at baseline (299 residents and 666 staff) were included in the analysis of primary and key secondary endpoints for assessing bamlanivimab as a preventative, while the 132 participants (41 residents and 91 staff) who tested positive for the virus at baseline were included in ex